Number (%) of patients with adverse events and global tolerability assessments by investigators and patients (intention to treat)
| Diclofenac patch (n = 60) | Placebo patch (n = 60) | |
|---|---|---|
| *Multiple citations possible. | ||
| Adverse event* (preferred term) | ||
| Pruritus | 2 (3.3) | 2 (3.3) |
| Erythematous rash | 3 (5.0) | 7 (11.7) |
| Pustular rash | 2 (3.3) | – |
| Global assessment of tolerability by investigators | ||
| Excellent | 56 (93.3) | 47 (78.3) |
| Good | 3 (5.0) | 10 (16.7) |
| Fair | – | 2 (3.3) |
| Poor | 1 (1.7) | 1 (1.7) |
| Global assessment of tolerability by patients | ||
| Missing | 2 (3.3) | – |
| Excellent | 44 (73.3) | 36 (60.0) |
| Good | 9 (15.0) | 15 (25.0) |
| Fair | 4 (6.7) | 6 (10.0) |
| Poor | 1 (1.7) | 3 (5.0) |